Abstract
This paper presents an SVEIRT epidemiological model in the human population with Chlamydia trachomatis. The model incorporated the vaccination class and investigated the role played by some control strategies in the dynamics of the disease (Chlamydia tracomatis). The reproduction number which helps in determining the rate of spread of the disease, was calculated using the method proosed by van den Driessche and Watmough. The local and global stability of the equlibrium points where established, where it was observed that the model is locally asymptotically stable if the reproduction number is less than unity, and globally stable if a certain threshold value is greater than unity or the re-nfection rate is zero. The effect of the re-infection rate on the global stability suggests the exhibition of the phenomenon of backward bifurcation of the model. The backward bifurcation of the system was later studied, and it shows that backward bifurcation will occur if the value of the bifurcation parameter ‘a’ is positive. The optimal control of the model shows the effect of different strategies in the transmission dynamicsof the disease and the cost effectivenes of each control pair. It was observed that the treatment and control effort gives the most cost effective combinations and at the same time the highest rate of disease avertion when compared to other stratagies. Sensitivity analysis of the parameters as shown in model, shows parameters that have high impact on the chosen classes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Federal University of Technology Owerri
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.